Homeobox B9 facilitates hypertrophic scar formation via activating the mitogen-activated protein kinase signaling pathway

Xie,Qun; Liu,Dandan; Yu,Mosheng; Wu,Xiaowei; Zhao,Yueqiang; Hu,Qiang; Wang,Qi

doi:10.3892/mmr.2017.6836

Homeobox B9 facilitates hypertrophic scar formation via activating the mitogen-activated protein kinase signaling pathway

Authors:
- Qun Xie
- Dandan Liu
- Mosheng Yu
- Xiaowei Wu
- Yueqiang Zhao
- Qiang Hu
- Qi Wang
View Affiliations

Affiliations: Department of Plastic Surgery, Xiangyang Central Hospital, Xiangyang, Hubei 441021, P.R. China, Department of Plastic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430000, P.R. China
Published online on: June 21, 2017 https://doi.org/10.3892/mmr.2017.6836
Pages: 1669-1676
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The functions and underlying mechanisms of homeobox B9 (HOXB9) in scar formation remain unclear; therefore, the present study aimed to investigate whether HOXB9 is highly expressed in hypertrophic scar formation. Immunohistochemistry was performed to examine the expression levels of laminin, fibronectin (FN), collagen type I (Col1) and HOXB9 in hypertrophic scar and healthy skin tissues, and in lentivirus‑constructed HOXB9‑overexpressed or ‑silenced fibroblasts (FBs). Reverse transcription‑quantitative polymerase chain reaction and western blotting were performed to evaluate the mRNA and protein expression levels of HOXB9, laminin, FN, Col1, extracellular signal‑regulated kinase (ERK), c‑Jun N‑terminal kinase (JNK), p38, p‑c‑Jun N‑terminal kinase (JNK), p‑ERK and p‑p38. A gel contraction assay was used to evaluate the effect of HOXB9 on FB contraction. Co‑immunoprecipitation assays were performed to verify the reciprocal interactions between HOXB9 and ERK, JNK and p38. It was demonstrated that HOXB9, laminin, FN and Col1 were upregulated in hypertrophic scar tissues, and HOXB9 upregulated laminin, FN, Col1, p‑ERK, p‑JNK and p38, potentially by interacting directly with p38. Furthermore, FBs overexpressing HOXB9 exhibited enhanced contractile capacity. In conclusion, the present study demonstrated that HOXB9 may facilitate hypertrophic scar formation via activating the mitogen‑activated protein kinase signaling pathway.

View Figures

View References

1	Rabello FB, Souza CD and Júnior JA Farina: Update on hypertrophic scar treatment. Clinics (Sao Paulo). 69:565–573. 2014. View Article : Google Scholar : PubMed/NCBI
2	Branski LK, Rennekampff HO and Vogt PM: Keloid and hypertrophic scar treatment modalities. An update. Chirurg. 83:831–846. 2012.(In German). View Article : Google Scholar
3	Hayashi T, Furukawa H, Oyama A, Funayama E, Saito A, Murao N and Yamamoto Y: A new uniform protocol of combined corticosteroid injections and ointment application reduces recurrence rates after surgical keloid/hypertrophic scar excision. Dermatol Surg. 38:893–897. 2012. View Article : Google Scholar : PubMed/NCBI
4	Huang D, Shen KH and Wang HG: Pressure therapy upregulates matrix metalloproteinase expression and downregulates collagen expression in hypertrophic scar tissue. Chin Med J (Engl). 126:3321–3324. 2013.PubMed/NCBI
5	Chesnut C, Mednik S and Lask G: Hypertrophic scar treatment with intralesional triamcinolone acetonide and pulsed dye laser results in necrosis. Cutis. 94:E12–E13. 2014.PubMed/NCBI
6	On HR, Lee SH, Lee YS, Chang HS, Park C and Roh MR: Evaluating hypertrophic thyroidectomy scar outcomes after treatment with triamcinolone injections and copper bromide laser therapy. Lasers Surg Med. 47:479–484. 2015. View Article : Google Scholar : PubMed/NCBI
7	Al-Mohamady Ael-S, Ibrahim SM and Muhammad MM: Pulsed dye laser versus long pulsed Nd:YAG laser in the treatment of hypertrophic scars and keloid: A comparative randomized split-scar trial. J Cosmet Laser Ther. 18:208–212. 2016. View Article : Google Scholar : PubMed/NCBI
8	Zhu Z, Ding J, Shankowsky HA and Tredget EE: The molecular mechanism of hypertrophic scar. J Cell Commun Signal. 7:239–252. 2013. View Article : Google Scholar : PubMed/NCBI
9	Werner S, Krieg T and Smola H: Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol. 127:998–1008. 2007. View Article : Google Scholar : PubMed/NCBI
10	Li B and Wang JH: Fibroblasts and myofibroblasts in wound healing: Force generation and measurement. J Tissue Viability. 20:108–120. 2011. View Article : Google Scholar : PubMed/NCBI
11	Gehring WJ, Affolter M and Bürglin T: Homeodomain proteins. Annu Rev Biochem. 63:487–526. 1994. View Article : Google Scholar : PubMed/NCBI
12	Apiou F, Flagiello D, Cillo C, Malfoy B, Poupon MF and Dutrillaux B: Fine mapping of human HOX gene clusters. Cytogenet Cell Genet. 73:114–115. 1996. View Article : Google Scholar : PubMed/NCBI
13	Mace KA, Hansen SL, Myers C, Young DM and Boudreau N: HOXA3 induces cell migration in endothelial and epithelial cells promoting angiogenesis and wound repair. J Cell Sci. 118:2567–2577. 2005. View Article : Google Scholar : PubMed/NCBI
14	Hansen SL, Myers CA, Charboneau A, Young DM and Boudreau N: HoxD3 accelerates wound healing in diabetic mice. Am J Pathol. 163:2421–2431. 2003. View Article : Google Scholar : PubMed/NCBI
15	Mack JA and Maytin EV: Persistent inflammation and angiogenesis during wound healing in K14-directed Hoxb13 transgenic mice. J Invest Dermatol. 130:856–865. 2010. View Article : Google Scholar : PubMed/NCBI
16	Mack JA, Abramson SR, Ben Y, Coffin JC, Rothrock JK, Maytin EV, Hascall VC, Largman C and Stelnicki EJ: Hoxb13 knockout adult skin exhibits high levels of hyaluronan and enhanced wound healing. FASEB J. 17:1352–1354. 2003.PubMed/NCBI
17	Chen F and Capecchi MR: Paralogous mouse Hox genes, Hoxa9, Hoxb9 and Hoxd9, function together to control development of the mammary gland in response to pregnancy. Proc Natl Acad Sci USA. 96:541–546. 1999. View Article : Google Scholar : PubMed/NCBI
18	Seki H, Hayashida T, Jinno H, Hirose S, Sakata M, Takahashi M, Maheswaran S, Mukai M and Kitagawa Y: HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients. Ann Surg Oncol. 19:1831–1840. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kwon OS, Oh E, Park JR, Lee JS, Bae GY, Koo JH, Kim H, Choi YL, Choi YS, Kim J and Cha HJ: GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma. Oncotarget. 6:41916–41928. 2015.PubMed/NCBI
20	Zhan J, Wang P, Niu M, Wang Y, Zhu X, Guo Y and Zhang H: High expression of transcriptional factor HoxB9 predicts poor prognosis in patients with lung adenocarcinoma. Histopathology. 66:955–965. 2015. View Article : Google Scholar : PubMed/NCBI
21	Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco Md, Wijendran V, Shioda T, et al: HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA. 107:1100–1105. 2010. View Article : Google Scholar : PubMed/NCBI
22	Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL and Massagué J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
23	Sha S, Gu Y, Xu B, Hu H, Yang Y, Kong X and Wu K: Decreased expression of HOXB9 is related to poor overall survival in patients with gastric carcinoma. Dig Liver Dis. 45:422–429. 2013. View Article : Google Scholar : PubMed/NCBI
24	Chang Q, Zhang L, He C, Zhang B, Zhang J, Liu B, Zeng N and Zhu Z: HOXB9 induction of mesenchymal-to-epithelial transition in gastric carcinoma is negatively regulated by its hexapeptide motif. Oncotarget. 6:42838–42853. 2015.PubMed/NCBI
25	He T, Bai X, Yang L, Fan L, Li Y, Su L, Gao J, Han S and Hu D: Loureirin B inhibits hypertrophic scar formation via inhibition of the TGF-β1-ERK/JNK Pathway. Cell Physiol Biochem. 37:666–676. 2015. View Article : Google Scholar : PubMed/NCBI
26	Root DE, Hacohen N, Hahn WC, Lander ES and Sabatini DM: Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods. 3:715–719. 2006. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Ngo P, Ramalingam P, Phillips JA and Furuta GT: Collagen gel contraction assay. Methods Mol Biol. 341:103–109. 2006.PubMed/NCBI
29	Vernon RB and Gooden MD: An improved method for the collagen gel contraction assay. In Vitro Cell Dev Biol Anim. 38:97–101. 2002. View Article : Google Scholar : PubMed/NCBI
30	Viera MH, Amini S, Valins W and Berman B: Innovative therapies in the treatment of keloids and hypertrophic scars. J Clin Aesthet Dermatol. 3:20–26. 2010.
31	Shaarawy E, Hegazy RA and Hay RM Abdel: Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: A randomized controlled trial. J Cosmet Dermatol. 14:161–166. 2015. View Article : Google Scholar : PubMed/NCBI
32	Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, Ruzicka T and Schauber J: Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol. 25:313–318. 2012. View Article : Google Scholar : PubMed/NCBI
33	Gauglitz GG, Korting HC, Pavicic T, Ruzicka T and Jeschke MG: Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategies. Mol Med. 17:113–125. 2011. View Article : Google Scholar : PubMed/NCBI
34	Xue M and Jackson CJ: Extracellular matrix reorganization during wound healing and its impact on abnormal scarring. Adv Wound Care (New Rochelle). 4:119–136. 2015. View Article : Google Scholar : PubMed/NCBI
35	Crean JK, Finlay D, Murphy M, Moss C, Godson C, Martin F and Brady HR: The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J Biol Chem. 277:44187–44194. 2002. View Article : Google Scholar : PubMed/NCBI
36	Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD and Franceschi RT: Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res. 17:101–110. 2002. View Article : Google Scholar : PubMed/NCBI
37	Qin H, Ishiwata T, Wang R, Kudo M, Yokoyama M, Naito Z and Asano G: Effects of extracellular matrix on phenotype modulation and MAPK transduction of rat aortic smooth muscle cells in vitro. Exp Mol Pathol. 69:79–90. 2000. View Article : Google Scholar : PubMed/NCBI
38	Kyriakis JM and Avruch J: Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update. Physiol Rev. 92:689–737. 2012. View Article : Google Scholar : PubMed/NCBI
39	Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI